MA34593B1 - Analogues de carba-nucleoside subtitues avec le 2'-fluoro pour le traitement antiviral - Google Patents
Analogues de carba-nucleoside subtitues avec le 2'-fluoro pour le traitement antiviralInfo
- Publication number
- MA34593B1 MA34593B1 MA35795A MA35795A MA34593B1 MA 34593 B1 MA34593 B1 MA 34593B1 MA 35795 A MA35795 A MA 35795A MA 35795 A MA35795 A MA 35795A MA 34593 B1 MA34593 B1 MA 34593B1
- Authority
- MA
- Morocco
- Prior art keywords
- substrated
- carba
- fluoro
- nucleoside analogues
- antiviral treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des nucléosides à imidazo[1,2-f][1,2,4]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/885,917 US7973013B2 (en) | 2009-09-21 | 2010-09-20 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
US13/050,820 US8455451B2 (en) | 2009-09-21 | 2011-03-17 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
PCT/US2011/029441 WO2012039791A1 (fr) | 2010-09-20 | 2011-03-22 | Analogues carbanucléosidiques 2'-fluoro-substitués pour traitement antiviral |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34593B1 true MA34593B1 (fr) | 2013-10-02 |
Family
ID=47748238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35795A MA34593B1 (fr) | 2010-09-20 | 2013-04-04 | Analogues de carba-nucleoside subtitues avec le 2'-fluoro pour le traitement antiviral |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP2619206A1 (fr) |
JP (4) | JP2013538230A (fr) |
KR (1) | KR101879887B1 (fr) |
CN (1) | CN103108876A (fr) |
AP (1) | AP3699A (fr) |
AU (1) | AU2011306066B2 (fr) |
BR (1) | BR112013008017A2 (fr) |
CA (1) | CA2807496C (fr) |
CL (1) | CL2013000727A1 (fr) |
CO (1) | CO6680669A2 (fr) |
CR (1) | CR20130172A (fr) |
EA (1) | EA026523B1 (fr) |
EC (1) | ECSP13012560A (fr) |
IL (1) | IL225221A0 (fr) |
MA (1) | MA34593B1 (fr) |
MX (1) | MX2013003179A (fr) |
NZ (1) | NZ608070A (fr) |
PE (3) | PE20171624A1 (fr) |
SG (1) | SG188223A1 (fr) |
WO (1) | WO2012039791A1 (fr) |
ZA (1) | ZA201301042B (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201334784A (zh) | 2008-04-23 | 2013-09-01 | Gilead Sciences Inc | 抗病毒性治療用的1’-經取代碳-核苷類似物 |
PT2480559E (pt) | 2009-09-21 | 2013-10-02 | Gilead Sciences Inc | Processos e intermediários para a preparação de análogos de 1'-ciano-carbanucleósido |
MA34471B1 (fr) | 2010-07-19 | 2013-08-01 | Gilead Sciences Inc | Procédés de préparation de promédicaments au phosphoramidate pur au plan diastéréomère |
UA111163C2 (uk) | 2010-07-22 | 2016-04-11 | Гайлід Сайєнсіз, Інк. | Способи й сполуки для лікування вірусних інфекцій paramyxoviridae |
US20130273005A1 (en) | 2010-12-20 | 2013-10-17 | Gilead Sciences, Inc. | Methods for treating hcv |
US9403863B2 (en) | 2011-09-12 | 2016-08-02 | Idenix Pharmaceuticals Llc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
UA119050C2 (uk) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類 |
CN104230985B (zh) * | 2014-09-01 | 2017-01-18 | 北京天弘天达医药科技有限公司 | (s)‑2‑[(s)‑(4‑硝基‑苯氧基)‑苯氧基‑磷酰基氨基]丙酸异丙酯的制备方法 |
TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
KR20230130175A (ko) | 2014-12-26 | 2023-09-11 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
EP3785717B1 (fr) | 2015-09-16 | 2022-01-05 | Gilead Sciences, Inc. | Méthodes de traitement d'infections dues aux coronaviridae |
ES2961460T3 (es) | 2017-03-14 | 2024-03-12 | Gilead Sciences Inc | Métodos para tratar las infecciones por coronavirus felinas |
WO2018204198A1 (fr) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Formes cristallines de (s) 2 éthylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)méthoxy)(phénoxy) phosphoryl)amino)propanoate |
US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
AU2018378832B9 (en) | 2017-12-07 | 2021-05-27 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
US11660307B2 (en) | 2020-01-27 | 2023-05-30 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
WO2021183750A2 (fr) | 2020-03-12 | 2021-09-16 | Gilead Sciences, Inc. | Procédés de préparation de 1 '-cyano nucléosides |
WO2021207049A1 (fr) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Formulations d'inhalation d'analogues de carbanucléosides à substitution 1'-cyano |
EP4157272A1 (fr) | 2020-05-29 | 2023-04-05 | Gilead Sciences, Inc. | Méthodes de traitement par remdesivir |
MX2022016405A (es) | 2020-06-24 | 2023-01-30 | Gilead Sciences Inc | Análogos de nucleósido de 1¿-ciano y usos de estos. |
JP2023540225A (ja) | 2020-08-27 | 2023-09-22 | ギリアード サイエンシーズ, インコーポレイテッド | ウイルス感染症の治療のための化合物及び方法 |
TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
WO2023207942A1 (fr) * | 2022-04-25 | 2023-11-02 | 北京沐华生物科技有限责任公司 | Médicament nucléosidique pour le traitement ou la prévention d'une infection à coronavirus, et son utilisation |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
ES2083580T3 (es) | 1990-06-13 | 1996-04-16 | Arnold Glazier | Profarmacos de fosforo. |
DK0481214T3 (da) | 1990-09-14 | 1999-02-22 | Acad Of Science Czech Republic | Prolægemidler af phosphonater |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
CA2389745C (fr) | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Procede de traitement ou de prevention de l'infection virale par flaviviridae faisant appel a des analogues des nucleosides |
SK11922002A3 (sk) | 2000-02-18 | 2003-06-03 | Shire Biochem Inc. | Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
PT1411954E (pt) | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
EP1539188B1 (fr) * | 2001-01-22 | 2015-01-07 | Merck Sharp & Dohme Corp. | Derives de nucleoside comme inhibiteurs de l'arn polymerase virale arn-dependante |
US20040006002A1 (en) | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
MXPA05005192A (es) | 2002-11-15 | 2005-09-08 | Idenix Cayman Ltd | Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae. |
CN100503628C (zh) * | 2003-05-30 | 2009-06-24 | 法莫赛特股份有限公司 | 修饰的氟化核苷类似物 |
KR101177590B1 (ko) | 2004-09-14 | 2012-08-27 | 파마셋 인코포레이티드 | 2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조 |
JP2008517912A (ja) * | 2004-10-21 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | RNA依存性RNAウイルス感染治療用フッ素化ピロロ[2,3−d]ピリミジンヌクレオシド |
CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA-依赖性RNA病毒感染的氟化吡咯并[2,3-d]嘧啶核苷 |
WO2006121820A1 (fr) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Promedicaments de phosphoramidate pour traitement d'infections virales |
WO2007027248A2 (fr) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | Analogues de nucleoside cyclique 3', 5' pour le traitement du virus de l'hepatite c (vhc) |
JP5116687B2 (ja) | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤 |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
CA2673649A1 (fr) | 2007-01-05 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Phosphoramidates d'aryle nucleosidiques destines au traitement de l'infection virale d'arn arn dependante |
JP2010515760A (ja) | 2007-01-12 | 2010-05-13 | バイオクライスト ファーマシューティカルズ, インコーポレイテッド | 抗ウイルス性ヌクレオシド類似体 |
CN101730699A (zh) | 2007-03-21 | 2010-06-09 | 百时美施贵宝公司 | 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物 |
PL2155758T3 (pl) | 2007-05-10 | 2013-06-28 | Biocryst Pharm Inc | Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka |
TW201334784A (zh) * | 2008-04-23 | 2013-09-01 | Gilead Sciences Inc | 抗病毒性治療用的1’-經取代碳-核苷類似物 |
WO2010036407A2 (fr) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Analogues nucléosidiques antiviraux |
EP2313102A2 (fr) * | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques |
UA112140C2 (uk) * | 2009-02-10 | 2016-07-25 | Гіліад Сайєнсіз, Інк. | Нуклеозидні похідіні (варіанти), фармацевтична композиція на їх основі, спосіб лікування вірусної інфекції та застосування сполуки для виробництва лікарського засобу |
PT2480552T (pt) * | 2009-09-21 | 2017-02-14 | Gilead Sciences Inc | Análogos de carba-nucleósidos 2¿ -fluoro substituídos para tratamento antiviral |
-
2011
- 2011-03-22 PE PE2017001530A patent/PE20171624A1/es unknown
- 2011-03-22 JP JP2013529139A patent/JP2013538230A/ja not_active Withdrawn
- 2011-03-22 AP AP2013006767A patent/AP3699A/en active
- 2011-03-22 CN CN2011800449231A patent/CN103108876A/zh active Pending
- 2011-03-22 BR BR112013008017A patent/BR112013008017A2/pt not_active Application Discontinuation
- 2011-03-22 KR KR1020137010012A patent/KR101879887B1/ko active IP Right Grant
- 2011-03-22 MX MX2013003179A patent/MX2013003179A/es not_active Application Discontinuation
- 2011-03-22 CA CA2807496A patent/CA2807496C/fr active Active
- 2011-03-22 AU AU2011306066A patent/AU2011306066B2/en active Active
- 2011-03-22 SG SG2013011325A patent/SG188223A1/en unknown
- 2011-03-22 PE PE2013000530A patent/PE20131165A1/es active IP Right Grant
- 2011-03-22 PE PE2022003082A patent/PE20230684A1/es unknown
- 2011-03-22 EA EA201390141A patent/EA026523B1/ru unknown
- 2011-03-22 WO PCT/US2011/029441 patent/WO2012039791A1/fr active Application Filing
- 2011-03-22 EP EP11715792.5A patent/EP2619206A1/fr not_active Withdrawn
- 2011-03-22 NZ NZ608070A patent/NZ608070A/en unknown
-
2013
- 2013-02-07 ZA ZA2013/01042A patent/ZA201301042B/en unknown
- 2013-02-26 CO CO13038918A patent/CO6680669A2/es not_active Application Discontinuation
- 2013-03-14 IL IL225221A patent/IL225221A0/en unknown
- 2013-03-18 CL CL2013000727A patent/CL2013000727A1/es unknown
- 2013-04-04 MA MA35795A patent/MA34593B1/fr unknown
- 2013-04-17 CR CR20130172A patent/CR20130172A/es unknown
- 2013-04-18 EC ECSP13012560 patent/ECSP13012560A/es unknown
-
2016
- 2016-01-18 JP JP2016006833A patent/JP2016074732A/ja not_active Withdrawn
-
2017
- 2017-04-10 JP JP2017077366A patent/JP6475280B2/ja active Active
-
2018
- 2018-09-18 JP JP2018173758A patent/JP2019014726A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2012039791A1 (fr) | 2012-03-29 |
IL225221A0 (en) | 2013-06-27 |
PE20171624A1 (es) | 2017-11-02 |
AP3699A (en) | 2016-05-31 |
EA026523B1 (ru) | 2017-04-28 |
KR20130110168A (ko) | 2013-10-08 |
AU2011306066A1 (en) | 2013-02-28 |
EA201390141A1 (ru) | 2013-09-30 |
BR112013008017A2 (pt) | 2016-06-14 |
KR101879887B1 (ko) | 2018-07-18 |
PE20131165A1 (es) | 2013-10-14 |
JP2017119726A (ja) | 2017-07-06 |
JP2016074732A (ja) | 2016-05-12 |
AP2013006767A0 (en) | 2013-03-31 |
CO6680669A2 (es) | 2013-05-31 |
ZA201301042B (en) | 2014-07-30 |
MX2013003179A (es) | 2013-04-24 |
JP2019014726A (ja) | 2019-01-31 |
CL2013000727A1 (es) | 2013-08-23 |
ECSP13012560A (es) | 2013-06-28 |
CR20130172A (es) | 2013-05-29 |
AU2011306066B2 (en) | 2015-01-29 |
JP2013538230A (ja) | 2013-10-10 |
CA2807496C (fr) | 2019-01-22 |
PE20230684A1 (es) | 2023-04-21 |
CN103108876A (zh) | 2013-05-15 |
CA2807496A1 (fr) | 2012-03-29 |
SG188223A1 (en) | 2013-04-30 |
NZ608070A (en) | 2015-11-27 |
EP2619206A1 (fr) | 2013-07-31 |
JP6475280B2 (ja) | 2019-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34593B1 (fr) | Analogues de carba-nucleoside subtitues avec le 2'-fluoro pour le traitement antiviral | |
HRP20170197T1 (hr) | 2' -fluoro supstituirani karba-nukleozidni analozi za antiviralno liječenje | |
AU2014270524A8 (en) | 2-phenylimidazo [1,2-a]pyrimidines as imaging agents | |
TW200635938A (en) | Fluorosurfactants | |
JO3154B1 (ar) | عوامل مضادة لـ trpv4 | |
HRP20181481T1 (hr) | D-metadon za liječenje psihijatrijskih simptoma | |
IN2015DN00515A (fr) | ||
PH12016500683A1 (en) | Synthetic route to 2`-deoxy-2`,2`-difluorotetrahydrouridines | |
MX2012007142A (es) | Uso de 2,3-dihidroxipropil dodecanoato para tratar seborrea. | |
MX347541B (es) | Analogos de acido sialico. | |
CR20110023A (es) | Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida | |
EA201400606A1 (ru) | Полиолефиновое волокно | |
MX2017003415A (es) | Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace. | |
MA38701A1 (fr) | Fond de poche et poche | |
UA98724C2 (en) | 4,3'-spiro[(2-amino-3-cyano-4,5-dihydro[3,2-c]chromene-5-one)-5-methyl-2'-oxindole] as nephroprotective agent | |
UA70312U (ru) | Применение антигельминтика "бровермектин - гранулят тм" как профилактически-лечебного средства при эктопаразитозах карповых рыб | |
DK201200555A (en) | Removal of heavy metals from wastewater by addition of dithiophosphate compounds | |
UA106373C2 (ru) | Применение поллентара как средства фригопротекторного действия | |
UA53769U (ru) | Способ переработки сульфата аммония | |
MX2015001134A (es) | Compuestos terapeuticos. | |
UA63370U (en) | Use of 4,3'-spiro[(2-amino-3-cyano-4,5-dihydropyrano[3,2-c]chromen-5-on)-5-methyl-2'-oxyndole] as nephroprotective agent | |
UA48043U (ru) | Применение перфторана в качестве эхоконтрастного препарата при проведении интервенционных эндоваскулярных вмешательств |